Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BML's stock price target?
Not Available
BML doesn't have any price targets made by Wall Street professionals.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Revenue forecast?
Projected CAGR
-13%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's revenue is 5%. The projected CAGR for the next 1 year is -13%.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Operating Income forecast?
Projected CAGR
-7%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's operating income is 15%. The projected CAGR for the next 1 year is -7%.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Net Income forecast?
Projected CAGR
8%
For the last 8 years the compound annual growth rate for Biomed Lublin Wytwornia Surowic i Szczepionek SA's net income is 64%. The projected CAGR for the next 1 year is 8%.
